CKPT — Checkpoint Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $103.54m
- $98.59m
- $0.10m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.71 | 1.07 | 0.268 | 0.192 | 0.103 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 26.6 | 24.3 | 57 | 58.5 | 52.3 |
Operating Profit | -24.9 | -23.2 | -56.7 | -58.3 | -52.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -24.7 | -23.1 | -56.7 | -62.6 | -51.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -24.7 | -23.1 | -56.7 | -62.6 | -51.8 |
Net Income Before Extraordinary Items | |||||
Net Income | -24.7 | -23.1 | -56.7 | -62.6 | -51.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -24.7 | -23.1 | -56.7 | -62.6 | -51.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -7 | -4.13 | -7.45 | -7.09 | -2.77 |